| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Mar'12 | Dec'11 |
|---|---|---|---|---|---|---|---|---|---|
License revenue | |||||||||
152 | 152 | 152 | 152 | 152 | 152 | 152 | 19 | - | 0 |
Costs and expenses: | |||||||||
Research and development: | |||||||||
Non cash stock expense associated with in-licensing agreements | |||||||||
100 | 4,000 | 0 | 0 | - | 5,350 | 0 | 16,578 | 16,875 | 297 |
Noncash compensation | |||||||||
5,811 | 5,598 | 5,647 | 2,742 | 4,261 | 8,731 | 1,041 | 455 | - | 0 |
Other research and development | |||||||||
148,269 | 149,793 | 96,886 | 66,490 | 43,445 | 26,004 | 12,621 | 3,994 | 193 | 30 |
Total research and development | |||||||||
154,180 | 159,391 | 102,533 | 69,232 | 47,707 | 40,086 | 13,662 | 21,027 | 17,068 | 327 |
General and administrative: | |||||||||
Noncash compensation | |||||||||
5,523 | 7,288 | 10,298 | 4,767 | 11,435 | 12,373 | 4,161 | 2,966 | - | 86 |
Non-cash compensation | |||||||||
- | - | - | - | - | - | - | - | 275 | - |
Other general and administrative | |||||||||
9,504 | 7,873 | 6,033 | 5,122 | 4,189 | 3,413 | 2,496 | 1,815 | 923 | 468 |
Total general and administrative | |||||||||
15,027 | 15,161 | 16,331 | 9,889 | 15,625 | 15,787 | 6,658 | 4,781 | 1,198 | 554 |
Impairment of in-process research and development | |||||||||
- | - | - | - | - | - | 2,797 | 1,104 | - | 0 |
Total costs and expenses | |||||||||
169,207 | 174,552 | 118,864 | 79,121 | 63,332 | 55,873 | 23,118 | 26,914 | 18,267 | 881 |
Operating loss | |||||||||
-169,055 | -174,400 | -118,712 | -78,969 | -63,180 | -55,721 | -22,965 | -26,895 | -18,267 | -881 |
Other (income) expense: | |||||||||
Interest expense | |||||||||
5,287 | 877 | 845 | - | - | - | 952 | 905 | -227 | 7 |
Interest expense | |||||||||
- | - | - | 323 | 174 | 55 | 30 | - | - | - |
Interest income | |||||||||
- | - | - | - | - | - | - | 15 | -3 | 0 |
Other income | |||||||||
1,471 | 1,795 | 1,081 | 393 | 56 | -115 | 108 | 272 | - | 0 |
Change in fair value of notes payable | |||||||||
- | - | - | - | - | - | 3,300 | 1,659 | -205 | 0 |
Total other expense (income), net | |||||||||
-3,816 | 918 | 236 | 716 | 231 | -60 | 2,487 | 1,042 | 18 | -7 |
Loss before income taxes | |||||||||
- | - | - | - | - | - | - | -25,852 | - | -889 |
Income taxes | |||||||||
- | - | - | - | - | - | - | 330 | - | 0 |
Net loss | |||||||||
-172,871 | -173,482 | -118,476 | -78,253 | -62,948 | -55,781 | -20,478 | -26,182 | -18,285 | -889 |
Net loss attributable to non-controlling interest | |||||||||
- | - | - | - | - | - | - | -8,110 | -7,176 | -35 |
Net loss attributable to TG Therapeutics, Inc. and Subsidiaries | |||||||||
- | - | - | - | - | - | - | -18,072 | -11,109 | -853 |
Basic and diluted net loss per common share (in dollars per share) | |||||||||
-1.96 | -2.30 | -1.91 | -1.60 | -1.38 | -1.64 | -0.81 | -1.38 | - | -0.44 |
Weighted average shares used in computing basic and diluted net loss per common share (in shares) | |||||||||
88,368 | 75,466 | 62,069 | 49,041 | 45,646 | 34,068 | 25,413 | 13,113 | - | 1,926 |